Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Ardea reports phase IIb RDEA-594 monotherapy data in hyperuricemia and gout

April 6, 2010

Merck & Co. selects antiobesity CB1 inverse agonist MK-5596 as clinical candidate

April 6, 2010

New SCD-1 inhibitors discovered by sanofi-aventis

April 6, 2010

FDA issues complete response letter on AstraZeneca and Abbott's Certriad NDA for mixed dyslipidemia

April 1, 2010

FDA accepts for review Savient's resubmitted Krystexxa BLA

March 31, 2010

Second-generation cholesterol absorption inhibitors discovered at Merck & Co.

March 31, 2010

EMA grants orphan drug designation to Protalix's taliglucerase alfa for Gaucher's disease

March 30, 2010

LCT receives approval to evaluate higher dose of DiabeCell in unstable diabetes

March 30, 2010

Potent and selective CB1 receptor antagonist shows promise in mouse model of obesity

March 30, 2010

Bayer to update label for oral contraceptive Yasmin in E.U.

March 29, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.